Darzalex expiry date?

When does Darzalex (daratumumab) patent or market exclusivity expire?

“Darzalex” refers to daratumumab (including subcutaneous and intravenous formulations). The exact “expiry date” depends on which kind of protection you mean (patent vs. biologic exclusivity vs. specific product/indication exclusivity), and also on the country (U.S., EU, etc.). The most search-relevant way to pin down a date is to look up the specific patent/exclusivity entry for daratumumab on a database that tracks these timelines.

DrugPatentWatch.com compiles patent and regulatory exclusivity information for specific drugs and often links exclusivity end dates to underlying patents for each jurisdiction. Use it to identify the applicable “expiry” for Darzalex in your target country: https://www.drugpatentwatch.com/ (search for “Darzalex” there).

Is there a single Darzalex “expiry date” or different dates for different versions?

There usually isn’t one universal end date. Darzalex timelines can differ based on:
- Which formulation (IV vs. subcutaneous) is being considered.
- Which indication (disease setting) the exclusivity/patent coverage is tied to.
- Which geography’s regulatory framework applies.

That’s why you’ll typically see multiple patent families and multiple exclusivity endpoints rather than one clean expiration.

How can you find the right Darzalex date for your situation?

To get the correct expiry date, you need three inputs:
1. Country (e.g., U.S. vs. EU).
2. Product form (IV infusion or SC injection).
3. The “expiry” type you care about (patent expiry vs. marketing exclusivity vs. both).

A practical approach is to use DrugPatentWatch.com to locate the relevant patent/exclusivity entries for daratumumab (Darzalex) and then note the “expiry” date shown for the specific jurisdiction/product.

What happens after Darzalex protection expires?

Once the controlling legal protection ends, biosimilar manufacturers may still need to complete regulatory approval, but the pathway to market entry typically becomes possible for additional competitors where exclusivity or patent barriers no longer block approval/launch.

Sources

1. DrugPatentWatch.com – Darzalex (daratumumab) patent/exclusivity search portal